Alissa Dei Cas
Medizinische Onkologie und Hämatologie · Dept. I
Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.
Oct 31, 2024
Clinical Studies - Oct 31, 2024 - Dec 31, 2028
Ongoing
Project leader: Fischer Stefanie
Members: Dei Cas Alissa
SAKK 66/22 - Invincible 4 SAKK
Oct 17, 2024Protocol SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immunochemotherapy in patients with early triple-negative breast cancer (TNBC). An openlabel randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK
Clinical Studies - Oct 17, 2024 - Dec 31, 2029
Ongoing
Project leader: Jörger Markus
Members: Dei Cas Alissa, Müller Fiona
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
Oct 7, 2024
Clinical Studies - Oct 7, 2024 - Oct 9, 2028
Ongoing
Project leader: Schittenhelm Marcus
Members: Dei Cas Alissa
MS201924_0002
Sep 30, 2024An open-label, multicenter, randomized Phase 2 study of the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in participants with BRCA mutant and/or homologous recombination deficiency (HRD) p...
Clinical Studies - Sep 30, 2024 - Sep 30, 2028
Ongoing
Project leader: Huober Jens
Members: Dei Cas Alissa, Müller Fiona